Physician profile
Benjamin Boone
NPI 1366974826
$79,930.06
in general payments reported to CMS, 2019-2025
26 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,894 · 2023: $4,744 · 2024: $27K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Food and Beverage: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $6,039 · Education: $12.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,735.00 |
| Food and Beverage | $15,500.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,750.00 |
| Travel and Lodging | $6,038.56 |
| Education | $12.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,565.25 | 2022-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $19,972.03 | 2022-2025 | Tavneos, Krystexxa, Enbrel |
| Novartis Pharmaceuticals Corporation | $14,093.85 | 2023-2025 | |
| Ucb, INC. | $6,846.49 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $3,137.38 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Mallinckrodt Hospital Products INC. | $807.32 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $711.36 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $677.99 | 2022-2025 | Saphnelo |
| Pfizer INC. | $622.95 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $445.44 | 2023-2025 | Orencia |
| Glaxosmithkline, LLC. | $443.18 | 2022-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $418.52 | 2022-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.06 | 2022-2025 | Ofev, Cyltezo |
| Sandoz INC. | $284.50 | 2023-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $248.18 | 2022-2025 | Strensiq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $223.21 | 2022-2025 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $196.99 | 2022-2024 | Tremfya |
| Genzyme Corporation | $193.60 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $157.51 | 2022-2025 | Lupkynis |
| Sobi, INC | $145.53 | 2023-2025 | |
| Organon LLC | $114.73 | 2023-2025 | Hadlima, Renflexis |
| Genentech USA, INC. | $72.35 | 2023-2024 | Actemra |
| Radius Health, INC. | $56.39 | 2022-2025 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $32.55 | 2025 | Uptravi |
| Fresenius Kabi USA, LLC | $29.72 | 2025 | Tyenne |
| United Therapeutics Corporation | $26.98 | 2024 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Boone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.